Karyopharm Therapeutics
Commercial-stage pharmaceutical company focused on discovery, development, and commercialization of small-molecule oncology therapies that act via inhibition of nuclear export (XPO1). Operates global clinical development programs across hematologic malignancies and solid tumors, maintains a commercial product available in multiple regions, and supports investigator-initiated research, expanded access, patient support, and medical affairs activities.
Industries
Nr. of Employees
large (251-1000)
Karyopharm Therapeutics
Newton Center, Massachusetts, United States
Patents
Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
US-12673939-B2
View DetailsProcess for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitors
US-12479806-B2
View Details
Methods of synthesis of heteroaryl derivatives of triazolyl acrylamides and crystalline forms
US-12673939-B2
View DetailsProcess for preparing XPO1 inhibitors and intermediates for use in the preparation of XPO1 inhibitors
US-12479806-B2
View DetailsProducts
Approved oral selective inhibitor of nuclear export (commercial-stage oncology medicine)
Commercially available oral small-molecule XPO1 inhibitor with regulatory approvals in multiple countries and use in oncology indications.
Clinical-stage oral nuclear export inhibitor candidates
Additional oral small-molecule nuclear export inhibitors in clinical development for hematologic and solid tumor indications.
Approved oral selective inhibitor of nuclear export (commercial-stage oncology medicine)
Commercially available oral small-molecule XPO1 inhibitor with regulatory approvals in multiple countries and use in oncology indications.
Clinical-stage oral nuclear export inhibitor candidates
Additional oral small-molecule nuclear export inhibitors in clinical development for hematologic and solid tumor indications.
Services
Review and potential support of independent research proposals with options for drug supply or drug supply plus funding; submission via an online portal.
Individual named patient access pathway for investigational medicines outside clinical trials under defined eligibility and regulatory requirements.
Medical information support and adverse event/product complaint intake for healthcare professionals and patients.
Mechanism for healthcare professionals to request scientific engagement with field medical staff.
Support services for patients prescribed commercially available therapies, including access assistance and educational resources.
Funding and sponsorship for unbiased, evidence-based medical education activities aligned to company focus areas.
Review and potential support of independent research proposals with options for drug supply or drug supply plus funding; submission via an online portal.
Individual named patient access pathway for investigational medicines outside clinical trials under defined eligibility and regulatory requirements.
Medical information support and adverse event/product complaint intake for healthcare professionals and patients.
Mechanism for healthcare professionals to request scientific engagement with field medical staff.
Support services for patients prescribed commercially available therapies, including access assistance and educational resources.
Funding and sponsorship for unbiased, evidence-based medical education activities aligned to company focus areas.
Expertise Areas
- Selective inhibition of nuclear export (XPO1) therapeutics
- Clinical trial management (Phase 1–3) in oncology
- Chemistry, manufacturing and controls (CMC) and process chemistry
- Regulatory strategy and global submissions
Key Technologies
- Selective inhibition of nuclear export (XPO1 inhibition)
- Oral small-molecule oncology therapeutics
- Clinical development across Phases I–III
- CMC and API process optimization